The role of CYP2D6 in the pharmacokinetics of ibogaine in healthy volunteers

This randomised, double-blind, placebo-controlled trial (n=24) investigates the role of CYP2D6 in the pharmacokinetics of ibogaine (20mg) in healthy volunteers.

The study, registered on ANZCTR with registration number ACTRN12613000324718, focuses on individuals with opioid dependence. Cohort A receives placebo, while Cohort B is given once daily oral doses of paroxetine to induce a CYP2D6 poor metabolizer phenotype. All participants receive a single oral dose of ibogaine (20mg) on Day 8.

Various outcomes, including plasma pharmacokinetics of ibogaine, safety, tolerability, and pharmacodynamics, are assessed. The primary objective is to characterise ibogaine to noribogaine conversion based on CYP2D6 activity. The trial, approved by the Southern Health and Disability Ethics Committee, University of Otago, New Zealand, commenced enrolment on July 1, 2013, and completed on September 15, 2013.

Topic Healthy Subjects
Compound Ibogaine Placebo
Country New Zealand
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

University of Otago
The University of Otago (specifically the Dunedin School of Medicine) is associated with psychedelic research but doesn't yet have a full profile.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.